CTT Pharmaceutical Holdings, Inc. has received formal approval from the SEC for its S-1 filing, making it an audited SEC reporting company on the OTCQB market. This milestone means CTT Pharma will now file SEC Form 8-K reports for significant events, increasing transparency for shareholders. The company specializes in innovative oral drug delivery systems and plans to continue updating investors as new developments arise.
Bitcoin's recent price recovery is supported by significant institutional investment, particularly through regulated ETFs, signaling a shift toward long-term ownership. Despite some volatility and a U.S. legislative setback on crypto regulation, infl...
The First Trust High Yield Opportunities 2027 Term Fund (FTHY) is experiencing near-term volatility and weak distribution coverage, with its discount widening despite an approaching liquidation date. However, the fund's term structure may lead to a v...
Glassnode's Altcoin Cycle Signal rose to 86 in June, indicating altcoins outperform Bitcoin, mainly due to Bitcoin's 18% drop rather than strong altcoin demand. By early July, the signal confirmed genuine altcoin strength, but by September, despite a...
The Bitwise Solana Staking ETF (BSOL) attracted over $60 million in new investments in the last two days, raising its assets under management to an all-time high of more than $1.2 billion. This surge reflects growing investor confidence in Solana's p...
Zappin, a new Telegram-based trading bot, launched on Robinhood Chain on September 21, allowing users to swap tokens via Uniswap and receive 90% of their trading fees back in ETH for 30 days. This promotion aims to attract early users to Robinhood's ...
